With new regulatory expectations coming to the fore for diversity action plans in Phase III studies, this session will focus on sharing the strategies deployed for actionable plans by on leading company.
CEU: 1.00 ACRP
Speakers:
A. Amanda Bishop, Associate Director, Clinical Trial Diversity Program Lead, Merck
Yael Symes, PhD, Senior Medical Writer, Merck
Watch a Sneak Peek into the Session Content: